ArticleGut pathogens2025
Effect of Moringa oleifera and ivermectin nanoparticles on the immunopathological response during experimental trichinosis in mice.
Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond Antioxidant Activity: Redox-Inflammatory Network Modulation as a Framework for the Multi-Organ Pharmacology ofJournal of experimental pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trichinella spiralis (T. spiralis) infection dynamically modulates macrophage polarization. It promotes M1 macrophage polarization, enhancing the pro-inflammatory pathways. This study investigates how ivermectin nanoparticles (IVM-NP) and Moringa oleifera leaf extract (MOL-NP) regulate these pathways to improve the pathophysiological outcomes of trichinosis. Thirty Swiss albino mice were infected with T. spiralis and divided equally into five groups of six mice each: healthy controls, infected untreated, IVM-NP-treated, MOL-NP-treated, and combined IVM-NP and MOL-NP-treated. IVM-NP were administered as a single oral dose of 200 µg/kg at the beginning of the experiment. MOL-NP were delivered orally at a dose of 400 mg/kg/day for 5 consecutive days starting from experiment initiation. Parasitological examination to detect the parasitic burden in addition to histopathological, immunohistochemical and quantitative histomorphometric assessment of intestinal tissue for nuclear factor kappa B (NF-κB) and inducible nitric oxide synthase (iNOS) were done. Furthermore, RT-PCR was performed to evaluate the relative gene expression of Arginase-1, TNF-α, and IL-10. Treatment with nanoparticle formulations of IVM and MOL modulated macrophage-related immune responses by reducing the pro-inflammatory markers iNOS, TNF-α and NF-κB, while increasing the relative gene expression of the anti-inflammatory cytokine IL-10. Combination therapy exhibited superior efficacy in decreasing parasite burden and mitigating intestinal pathology compared to monotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.